A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This single arm study will evaluate the efficacy and safety of MabThera in patients with
active rheumatoid arthritis whose current treatment with one or more TNF blocker had produced
an inadequate response. Patients will receive MabThera (1g infusion) on day 1 and day 15, and
will continue on their basic methotrexate therapy (10-25mg/week). The anticipated time on
study treatment is 3-12 months, and the target sample size is <100 individuals.